EyeGene Inc. (KOSDAQ:185490)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,605.00
-15.00 (-0.57%)
Feb 21, 2025, 9:00 AM KST
-18.47%
Market Cap 70.01B
Revenue (ttm) 3.26B
Net Income (ttm) -14.09B
Shares Out 27.03M
EPS (ttm) -658.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,305
Average Volume 26,275
Open 2,660.00
Previous Close 2,620.00
Day's Range 2,590.00 - 2,700.00
52-Week Range 2,430.00 - 4,720.00
Beta 1.47
RSI 42.64
Earnings Date Mar 14, 2025

About EyeGene

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 41
Stock Exchange KOSDAQ
Ticker Symbol 185490
Full Company Profile

Financial Performance

In 2023, EyeGene's revenue was 3.13 billion, a decrease of -40.96% compared to the previous year's 5.29 billion. Losses were -21.11 billion, -18.68% less than in 2022.

Financial Statements

News

There is no news available yet.